CY1105842T1 - Τροποποιημενες v πρωτεϊνες ιου ιλαρας - Google Patents
Τροποποιημενες v πρωτεϊνες ιου ιλαραςInfo
- Publication number
- CY1105842T1 CY1105842T1 CY20061101780T CY061101780T CY1105842T1 CY 1105842 T1 CY1105842 T1 CY 1105842T1 CY 20061101780 T CY20061101780 T CY 20061101780T CY 061101780 T CY061101780 T CY 061101780T CY 1105842 T1 CY1105842 T1 CY 1105842T1
- Authority
- CY
- Cyprus
- Prior art keywords
- modified
- measles virus
- proteins
- amino acids
- measles
- Prior art date
Links
- 241000712079 Measles morbillivirus Species 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 201000005505 Measles Diseases 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 101900047836 Measles virus Non-structural protein V Proteins 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18461—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21365500P | 2000-06-23 | 2000-06-23 | |
| PCT/US2001/019806 WO2002000694A2 (en) | 2000-06-23 | 2001-06-21 | Modified morbillivirus v proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1105842T1 true CY1105842T1 (el) | 2011-02-02 |
Family
ID=22795965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20061101780T CY1105842T1 (el) | 2000-06-23 | 2006-12-11 | Τροποποιημενες v πρωτεϊνες ιου ιλαρας |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6664066B2 (https=) |
| EP (1) | EP1292615B1 (https=) |
| JP (1) | JP2004513616A (https=) |
| KR (1) | KR100885325B1 (https=) |
| CN (1) | CN1298738C (https=) |
| AT (1) | ATE343589T1 (https=) |
| AU (2) | AU2001267014B2 (https=) |
| BR (1) | BR0111827A (https=) |
| CA (1) | CA2409432C (https=) |
| CY (1) | CY1105842T1 (https=) |
| DE (1) | DE60124098T2 (https=) |
| DK (1) | DK1292615T3 (https=) |
| ES (1) | ES2273852T3 (https=) |
| IL (1) | IL153004A0 (https=) |
| MX (1) | MXPA02012256A (https=) |
| PT (1) | PT1292615E (https=) |
| WO (1) | WO2002000694A2 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE490267T1 (de) * | 2001-06-05 | 2010-12-15 | Curevac Gmbh | Stabilisierte mrna mit erhöhtem g/c-gehalt, kodierend für ein virales antigen |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| DE10229872A1 (de) * | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
| CN1871355B (zh) | 2003-06-09 | 2011-12-14 | 惠氏 | 从cDNA中回收非节段性负链RNA病毒的改进方法 |
| DE102004042546A1 (de) * | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
| AU2007280690C1 (en) | 2006-07-31 | 2012-08-23 | Curevac Gmbh | Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant |
| EP2069485A4 (en) * | 2007-07-13 | 2011-05-25 | Medimmune Llc | PREPARATION OF NEGATIVE STRAND RNA VIRUSES BY ELECTROPORATION |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| EP2176408B9 (en) | 2008-01-31 | 2015-11-11 | Curevac GmbH | NUCLEIC ACIDS COMPRISING FORMULA (NuGiXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| CA2801523C (en) | 2010-07-30 | 2021-08-03 | Curevac Gmbh | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2013120302A (ru) | 2010-10-01 | 2014-11-20 | Модерна Терапьютикс, Инк. | Сконструированные нуклеиновые кислоты и способы их применения |
| EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
| CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
| EP2804948B1 (en) * | 2012-01-20 | 2020-04-15 | The Government of The Hong Kong Special Administrative Region of The People's Republic of China | A novel paramyxovirus and uses thereof |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| WO2014081507A1 (en) | 2012-11-26 | 2014-05-30 | Moderna Therapeutics, Inc. | Terminally modified rna |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| BR112016003361A2 (pt) | 2013-08-21 | 2017-11-21 | Curevac Ag | vacina do vírus sincicial respiratório (rsv) |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| ES2806575T3 (es) | 2013-11-01 | 2021-02-18 | Curevac Ag | ARN modificado con propiedades inmunoestimuladoras disminuidas |
| CA2936286A1 (en) | 2014-04-01 | 2015-10-08 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
| US11100434B2 (en) | 2014-05-06 | 2021-08-24 | Uber Technologies, Inc. | Real-time carpooling coordinating system and methods |
| US10458801B2 (en) | 2014-05-06 | 2019-10-29 | Uber Technologies, Inc. | Systems and methods for travel planning that calls for at least one transportation vehicle unit |
| US9552559B2 (en) | 2014-05-06 | 2017-01-24 | Elwha Llc | System and methods for verifying that one or more directives that direct transport of a second end user does not conflict with one or more obligations to transport a first end user |
| WO2015171762A1 (en) | 2014-05-06 | 2015-11-12 | Elwha Llc | System and methods for travel planning that calls for at least one transportation vehicle unit |
| CA2955124C (en) * | 2014-07-18 | 2024-01-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Peptides including a binding domain of the viral phosphoprotein (p) subunit to the viral rna free nucleoprotein (n0) |
| WO2016029168A1 (en) | 2014-08-21 | 2016-02-25 | Uber Technologies, Inc. | Arranging a transport service for a user based on the estimated time of arrival of the user |
| US10685416B2 (en) | 2015-12-10 | 2020-06-16 | Uber Technologies, Inc. | Suggested pickup location for ride services |
| US10731998B2 (en) | 2017-11-05 | 2020-08-04 | Uber Technologies, Inc. | Network computer system to arrange pooled transport services |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT702085E (pt) | 1994-07-18 | 2004-04-30 | Karl Klaus Conzelmann | Virus de arn de cadeia negativa nao segmentada infeccioso recombinante |
| ATE181112T1 (de) | 1995-08-09 | 1999-06-15 | Schweiz Serum & Impfinst | Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren |
| KR20000048628A (ko) | 1996-09-27 | 2000-07-25 | 윌리암 에이취 캘넌, 에곤 이 버그 | 모노네가비랄레스 목의 바이러스에서 감쇠를 책임지는 3' 게놈프로모터 영역 및 폴리머라제 유전자 돌연변이 |
| KR100702523B1 (ko) | 1997-05-23 | 2007-04-04 | 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 에즈 레프리젠티드 바이 더 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈 | 클로닝된 뉴클레오타이드 서열로부터 약독화된파라인플루엔자 바이러스를 제조하는 방법 |
| JP2002507408A (ja) * | 1998-03-26 | 2002-03-12 | アメリカン・サイアナミド・カンパニー | 麻疹ウイルスもしくはヒト呼吸合胞体ウイルスサブグループｂの弱毒化の原因である突然変異 |
-
2001
- 2001-06-21 CN CNB018116426A patent/CN1298738C/zh not_active Expired - Fee Related
- 2001-06-21 CA CA2409432A patent/CA2409432C/en not_active Expired - Fee Related
- 2001-06-21 IL IL15300401A patent/IL153004A0/xx unknown
- 2001-06-21 US US10/311,582 patent/US6664066B2/en not_active Expired - Fee Related
- 2001-06-21 DK DK01944623T patent/DK1292615T3/da active
- 2001-06-21 AU AU2001267014A patent/AU2001267014B2/en not_active Ceased
- 2001-06-21 WO PCT/US2001/019806 patent/WO2002000694A2/en not_active Ceased
- 2001-06-21 ES ES01944623T patent/ES2273852T3/es not_active Expired - Lifetime
- 2001-06-21 PT PT01944623T patent/PT1292615E/pt unknown
- 2001-06-21 BR BR0111827-7A patent/BR0111827A/pt not_active Application Discontinuation
- 2001-06-21 DE DE60124098T patent/DE60124098T2/de not_active Expired - Lifetime
- 2001-06-21 AU AU6701401A patent/AU6701401A/xx active Pending
- 2001-06-21 KR KR1020027017494A patent/KR100885325B1/ko not_active Expired - Fee Related
- 2001-06-21 EP EP01944623A patent/EP1292615B1/en not_active Expired - Lifetime
- 2001-06-21 MX MXPA02012256A patent/MXPA02012256A/es active IP Right Grant
- 2001-06-21 JP JP2002505816A patent/JP2004513616A/ja active Pending
- 2001-06-21 AT AT01944623T patent/ATE343589T1/de not_active IP Right Cessation
-
2006
- 2006-12-11 CY CY20061101780T patent/CY1105842T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2409432A1 (en) | 2002-01-03 |
| AU2001267014B2 (en) | 2007-03-15 |
| MXPA02012256A (es) | 2003-04-25 |
| US20030206925A1 (en) | 2003-11-06 |
| DE60124098D1 (de) | 2006-12-07 |
| EP1292615B1 (en) | 2006-10-25 |
| PT1292615E (pt) | 2007-01-31 |
| WO2002000694A2 (en) | 2002-01-03 |
| ES2273852T3 (es) | 2007-05-16 |
| ATE343589T1 (de) | 2006-11-15 |
| EP1292615A2 (en) | 2003-03-19 |
| JP2004513616A (ja) | 2004-05-13 |
| BR0111827A (pt) | 2003-05-20 |
| US6664066B2 (en) | 2003-12-16 |
| DE60124098T2 (de) | 2007-04-05 |
| CN1437613A (zh) | 2003-08-20 |
| CN1298738C (zh) | 2007-02-07 |
| DK1292615T3 (da) | 2007-02-19 |
| KR20030032971A (ko) | 2003-04-26 |
| CA2409432C (en) | 2010-08-03 |
| KR100885325B1 (ko) | 2009-02-25 |
| AU6701401A (en) | 2002-01-08 |
| WO2002000694A3 (en) | 2002-10-10 |
| IL153004A0 (en) | 2003-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1105842T1 (el) | Τροποποιημενες v πρωτεϊνες ιου ιλαρας | |
| CY1109649T1 (el) | Αντιγονα και συνθεσεις απο neisseria | |
| PL1685243T3 (pl) | Unieśmiertelnione ptasie linie komórkowe do wytwarzania wirusów | |
| CY1114265T1 (el) | Πρωτεϊνη συντηξης αλβουμινης | |
| CY1111006T1 (el) | Εκριμματαση ασθενειας alzheimer | |
| BR0316435A (pt) | Produtos genéticos expressos diferencialmente em tumores e uso dos mesmos | |
| DE69839557D1 (de) | Klonierte genome von infektiösen hepatitis c viren und deren verwendungen | |
| DE3686304D1 (de) | Typenspezifische papillomavirus-dns-sequenzen und peptide. | |
| DE69935986D1 (de) | Streptococcus pneumoniae proteine und nukleinsäuren | |
| DK1265914T3 (da) | WNT-1-relaterede polypeptider og nukleinsyrer, der koder for samme | |
| ATE393234T1 (de) | Adenovirale vektoren und eine methode zur reduktion von homologer rekombination | |
| DE50112802D1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
| CY1117746T1 (el) | Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna | |
| DE60230456D1 (de) | Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren | |
| DE69819124D1 (de) | Lyophilisation von kultivierten, menschlichen zellen zur konservierung der rna und dna | |
| DE69928395D1 (de) | Cyclin-e2 proteine und dafür kodierende gene | |
| WO2002027007A3 (en) | Production of viral vectors | |
| DK1276763T3 (da) | Anti-fryseproteiner, deres fremstilling og anvendelse | |
| CY1106433T1 (el) | Εμβολια κοκκιδιωσης | |
| DE60034884D1 (de) | Klonierte genome von infektiösen hepatitis c viren genotyp 2a und deren verwendungen | |
| ATE435277T1 (de) | 18477, eine menschliche proteinkinase und deren verwendung | |
| CY1105405T1 (el) | Dna και πολυπεπτιδια il-1ζ, παραλλαγων ματισματος il-1ζ και xrec2 | |
| AU1572702A (en) | Novel immunomodulatory protein and useful embodiments thereof | |
| DE69937998D1 (de) | Antiproliferative und antivirale proteine und peptide | |
| NO20005321L (no) | Vertskodet protein uttrykt i Mareks sykdoms (MDV) infiserte celler og antistoffer til dette |